Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.
Emsere, headquartered in Leiden in the Netherlands, is a medical equipment rental specialist providing clinical trial equipment and logistics solutions to pharmaceutical companies and contract research organisations (CROs) globally.
Founded in 1996, Emsere manages over 13,000 pieces of equipment and delivers to more than 100 countries, serving six of the top 10 global pharmaceutical companies and seven of the top 10 CROs. Its portfolio includes centrifuges, imaging devices, cardiovascular and respiratory monitors, and cardio-pulmonary exercise testing equipment.
The company operates in the growing clinical trial equipment rental market, addressing demand for outsourced, complex, and regulatory-compliant solutions delivered at scale. Emsere's services allow clients to focus on scientific and clinical execution while avoiding capital expenditure and logistical coordination.
Antin's investment marks the eighth for its EUR2.2bn Mid Cap Fund I and continues its strategy of scaling health and medical infrastructure companies in Europe and North America. Emsere's CEO Patrice Gerard and senior management will co-invest alongside Antin.
The transaction is expected to close in the first quarter of 2026.
Advita Ortho updates Chime clinical exchange application
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Boston Scientific to acquire Valencia Technologies to expand overactive bladder portfolio